Overview

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.

Phase:

Phase 1

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Pfizer

Treatments:

Everolimus
Gedatolisib
Palbociclib
Sirolimus